Loss of heterozygosity at 1p, 8p, 10p, 13q, and 17p in advanced urothelial cancer and lack of relation to chemotherapy response and outcome

This publication has 29 references indexed in Scilit:

• Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma
  International Journal of Cancer, 1999
• Selective Killing of Cancer Cells Based on Loss of Heterozygosity and Normal Variation in the Human Genome: A New Paradigm for Anticancer Drug Therapy
  Molecular Pharmacology, 1999
• Localization of tumor suppressor gene associated with distant metastasis of urinary bladder cancer to a 1-Mb interval on 8p22
  Genes, Chromosomes and Cancer, 1999
• Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic Oligodendrogliomas
  JNCI Journal of the National Cancer Institute, 1998
• Molecular alterations in bladder cancer.
  Urological Research, 1998
• Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
  Journal of Clinical Oncology, 1997
• Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy
  British Journal of Cancer, 1996
• Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma.
  Journal of Clinical Oncology, 1996
• Platinum analogue combination chemotherapy: Cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors
  Cancer, 1995
• Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract
  Cancer, 1994